Side-by-Side Comparison · 2026

Albuvirtide vs Enfuvirtide

Albuvirtide vs Enfuvirtide — mechanism, half-life, dosing, and research status compared. Which is right for your protocol?

Albuvirtide
Antiviral Peptide

Albuvirtide is a long-acting HIV-1 fusion inhibitor approved in China in 2018. It is derived from the HR2 region of HIV-1 gp41 and is conjugated to a fatty acid that enables albumin binding, extending its half-life to approximately 11-12 days....

Calculate Albuvirtide dose →
Enfuvirtide
Antiviral Peptide

Enfuvirtide (T-20, Fuzeon) is a 36-residue synthetic peptide derived from the C-terminal heptad repeat (CHR) of HIV-1 gp41. Approved by the FDA in 2003, it was the first HIV fusion inhibitor and the first approved antiviral peptide drug....

Calculate Enfuvirtide dose →
Key Parameters
Parameter Albuvirtide Enfuvirtide
Category Antiviral Peptide Antiviral Peptide
Research Approved (China) FDA Approved
Half-Life 11-12 days 3.8 hours
Typical Dose 320 mg once weekly 90 mg twice daily
Frequency Once weekly Twice daily
Route Intravenous Subcutaneous injection
FDA Status Not approved (approved China 2018) Approved (HIV-1, 2003)

Calculate doses for both

Use ASCEND's free reconstitution calculator to get exact syringe draw amounts for your vial.

Calculate Albuvirtide Calculate Enfuvirtide
Frequently Asked Questions
What is the difference between Albuvirtide and Enfuvirtide?
Albuvirtide: Albuvirtide is a long-acting HIV-1 fusion inhibitor approved in China in 2018. It is derived from the HR2 region of HIV-1 gp41 and is conjugated to a fatty acid that enables albumin binding, extending... Enfuvirtide: Enfuvirtide (T-20, Fuzeon) is a 36-residue synthetic peptide derived from the C-terminal heptad repeat (CHR) of HIV-1 gp41. Approved by the FDA in 2003, it was the first HIV fusion inhibitor and the f...
Which has a longer half-life, Albuvirtide or Enfuvirtide?
Albuvirtide half-life: 11-12 days. Enfuvirtide half-life: 3.8 hours.
Can you stack Albuvirtide and Enfuvirtide?
Albuvirtide and Enfuvirtide are in the same category and used together in research protocols. Always consult relevant literature and follow appropriate guidelines.

For research use only. Not medical advice. ASCEND does not conduct or endorse any specific research protocol. Always consult relevant scientific literature and regulatory guidelines.